Genetic Dystonias: Update on Classification and New Genetic Discoveries.


Journal

Current neurology and neuroscience reports
ISSN: 1534-6293
Titre abrégé: Curr Neurol Neurosci Rep
Pays: United States
ID NLM: 100931790

Informations de publication

Date de publication:
09 02 2021
Historique:
accepted: 13 01 2021
entrez: 10 2 2021
pubmed: 11 2 2021
medline: 28 4 2021
Statut: epublish

Résumé

Since the advent of next-generation sequencing, the number of genes associated with dystonia has been growing exponentially. We provide here a comprehensive review of the latest genetic discoveries in the field of dystonia and discuss how the growing knowledge of biology underlying monogenic dystonias may influence and challenge current classification systems. Pathogenic variants in genes without previously confirmed roles in human disease have been identified in subjects affected by isolated or combined dystonia (KMT2B, VPS16, HPCA, KCTD17, DNAJC12, SLC18A2) and complex dystonia (SQSTM1, IRF2BPL, YY1, VPS41). Importantly, the classical distinction between isolated and combined dystonias has become harder to sustain since many genes have been shown to determine multiple dystonic presentations (e.g., ANO3, GNAL, ADCY5, and ATP1A3). In addition, a growing number of genes initially linked to other neurological phenotypes, such as developmental delay, epilepsy, or ataxia, are now recognized to cause prominent dystonia, occasionally in an isolated fashion (e.g., GNAO1, GNB1, SCN8A, RHOBTB2, and COQ8A). Finally, emerging analyses suggest biological convergence of genes linked to different dystonic phenotypes. While our knowledge on the genetic basis of monogenic dystonias has tremendously grown, their clinical boundaries are becoming increasingly blurry. The current phenotype-based classification may not reflect the molecular structure of the disease, urging the need for new systems based on shared biological pathways among dystonia-linked genes.

Identifiants

pubmed: 33564903
doi: 10.1007/s11910-021-01095-1
pii: 10.1007/s11910-021-01095-1
doi:

Substances chimiques

ANO3 protein, human 0
ATP1A3 protein, human 0
Anoctamins 0
Carrier Proteins 0
GNAO1 protein, human 0
IRF2BPL protein, human 0
Nuclear Proteins 0
GTP-Binding Protein alpha Subunits, Gi-Go EC 3.6.5.1
Sodium-Potassium-Exchanging ATPase EC 7.2.2.13

Types de publication

Journal Article Research Support, Non-U.S. Gov't Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

8

Auteurs

Ignacio Juan Keller Sarmiento (IJ)

Department of Neurology, Feinberg School of Medicine, Northwestern University, Chicago, IL, 60611, USA.

Niccolò Emanuele Mencacci (NE)

Department of Neurology, Feinberg School of Medicine, Northwestern University, Chicago, IL, 60611, USA. niccolo.mencacci@northwestern.edu.

Articles similaires

Genome, Chloroplast Phylogeny Genetic Markers Base Composition High-Throughput Nucleotide Sequencing

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C

Classifications MeSH